GNLX vs. CRMD, NATR, MRSN, ADCT, RANI, ANL, ENTA, ME, ATAI, and AQST
Should you be buying Genelux stock or one of its competitors? The main competitors of Genelux include CorMedix (CRMD), Nature's Sunshine Products (NATR), Mersana Therapeutics (MRSN), ADC Therapeutics (ADCT), Rani Therapeutics (RANI), Adlai Nortye (ANL), Enanta Pharmaceuticals (ENTA), 23andMe (ME), Atai Life Sciences (ATAI), and Aquestive Therapeutics (AQST). These companies are all part of the "pharmaceutical preparations" industry.
CorMedix (NASDAQ:CRMD) and Genelux (NASDAQ:GNLX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings, analyst recommendations and community ranking.
34.2% of CorMedix shares are held by institutional investors. Comparatively, 37.3% of Genelux shares are held by institutional investors. 3.6% of CorMedix shares are held by insiders. Comparatively, 11.7% of Genelux shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
In the previous week, Genelux had 2 more articles in the media than CorMedix. MarketBeat recorded 5 mentions for Genelux and 3 mentions for CorMedix. Genelux's average media sentiment score of 1.07 beat CorMedix's score of -0.12 indicating that CorMedix is being referred to more favorably in the media.
CorMedix received 6 more outperform votes than Genelux when rated by MarketBeat users. However, 100.00% of users gave Genelux an outperform vote while only 71.43% of users gave CorMedix an outperform vote.
Genelux's return on equity of -77.17% beat CorMedix's return on equity.
Genelux has lower revenue, but higher earnings than CorMedix. CorMedix is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks.
CorMedix has a beta of 1.79, suggesting that its stock price is 79% more volatile than the S&P 500. Comparatively, Genelux has a beta of -1.18, suggesting that its stock price is 218% less volatile than the S&P 500.
CorMedix currently has a consensus price target of $13.00, suggesting a potential upside of 146.68%. Genelux has a consensus price target of $32.33, suggesting a potential upside of 1,093.11%. Given CorMedix's higher probable upside, analysts clearly believe Genelux is more favorable than CorMedix.
Summary
Genelux beats CorMedix on 8 of the 15 factors compared between the two stocks.
Get Genelux News Delivered to You Automatically
Sign up to receive the latest news and ratings for GNLX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GNLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
